Claris Law Legal Blogging Community

Recent Entries

RSS 2.0 feed Add to My Yahoo!
Add to Bloglines Add to your My Feedster
Add to your NewsGator My MSN
Avandia Lawsuit Heart Attack Attorney

More Deceit from GlaxoSmithKline

editor photo

Editor: Robert J. Binstock
Profession: Avandia Attorney

September 17, 2007

By Scott Kappes

TrackBack (0)

Category: Avandia Heart Attack

Two British pension funds are vying to be lead plaintiffs in a U.S. class action lawsuit filed against GlaxoSmithKline for misleading investors about the risks of Avandia. The North Yorkshire Pension Fund and the Avon Pension Fund manage about $6 billion of their members assets. Many GlaxoSmithKline investors are dissatisfied with the companies share prices since the New England Journal of Medicine published a study linking one of their best selling drugs, Avandia, to an increased risk of heart failure.

The findings of the study showed a 42 percent increased risk of heart failure associated with Avandia. The study sent a shock through the industry and took about $18 billion off of GSK's market capitalization.

The lawsuit alleges Glaxo "engaged in a scheme to deceive the market and a course of conduct that artificially inflated GSK's stock price" and "failed to adequately disclose" important risk info. Glaxo is accused of "fraud" and "deceit." A spokesman for GSK said that the company believed the lawsuit had no merit and would vigorously defend itself.

The FDA has recently required GSK to place a new heart failure warning on Avandia warning of this increased heart risk. A panel voted to impose the new "black box" warning, instead if pulling the drug from the market.

Trackback Pings

TrackBack URL for this entry:

Email Article